Ovarian Cancer pp 189-202 | Cite as

Soluble Epidermal Growth Factor Receptor: A Biomarker of Epithelial Ovarian Cancer

  • Andre T. BaronEmail author
  • Jacqueline M. Lafky
  • Cecelia H. Boardman
  • Elsa M. Cora
  • Marites C. Buenafe
  • Dachao Liu
  • Alfred Rademaker
  • David A. Fishman
  • Karl C. Podratz
  • Jill L. Reiter
  • Nita J. Maihle
Part of the Cancer Treatment and Research book series (CTAR, volume 149)

Definition: The Epidermal Growth Factor Receptor and Soluble Epidermal Growth Factor Receptor Isoforms

The epidermal growth factor receptor (EGFR) is the prototypic member of the ErbB receptor tyrosine kinase family, which includes ErbB1 (EGFR), ErbB2 (HER2, Neu), ErbB3 (HER3), and ErbB4 (HER4).1, 2, 3 Biochemical and structural studies show that the mature form of EGFR is a 170-kDa plasma membrane protein that is composed of extracellular, transmembrane-spanning, and intracellular domains.4The extracellular domain is divided into four subdomains: subdomains I and III function in growth factor binding, and subdomains II and IV confer secondary and tertiary structure to the extracellular domain through cysteine residues. The intracellular domain also is divided into subdomains: a tyrosine kinase subdomain and a carboxy-terminal regulatory subdomain that includes several tyrosine autophosphorylation sites. In general, growth factor binding to EGFR results in receptor dimerization with...


Epidermal Growth Factor Receptor Epithelial Ovarian Cancer Cytoreductive Surgery Epithelial Ovarian Carcinoma Granulosa Cell Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem. 1993;62:453–481.PubMedGoogle Scholar
  2. 2.
    Peles E, Yarden Y. Neu and its ligands: from an oncogene to neural factors. Bioessays. 1993;15(12):815–824.CrossRefPubMedGoogle Scholar
  3. 3.
    Maihle NJ, Baron AT, Barrette BA, et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res. 2002;107:247–258.PubMedGoogle Scholar
  4. 4.
    Yarden Y, Ullrich A. Molecular analysis of signal transduction by growth factors. Biochemistry. 1988;27(9):3113–3119.CrossRefPubMedGoogle Scholar
  5. 5.
    Koch CA, Anderson D, Moran MF, Ellis C, Pawson T. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science. 1991;252(5006):668–674.CrossRefPubMedGoogle Scholar
  6. 6.
    Kavanaugh WM, Williams LT. An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science. 1994;266(5192):1862–1865.CrossRefPubMedGoogle Scholar
  7. 7.
    Adamson ED. EGF receptor activities in mammalian development. Mol Reprod Dev. 1990;27(1):16–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Wiley LM, Adamson ED, Tsark EC. Epidermal growth factor receptor function in early mammalian development. Bioessays. 1995;17(10):839–846.CrossRefPubMedGoogle Scholar
  9. 9.
    Petch LA, Harris J, Raymond VW, Blasband A, Lee DC, Earp HS. A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue. Mol Cell Biol. 1990;10(6):2973–2982.PubMedGoogle Scholar
  10. 10.
    Das SK, Tsukamura H, Paria BC, Andrews GK, Dey SK. Differential expression of epidermal growth factor receptor (EGF-R) gene and regulation of EGF-R bioactivity by progesterone and estrogen in the adult mouse uterus. Endocrinology. 1994;134:971–981.CrossRefPubMedGoogle Scholar
  11. 11.
    Tong BJ, Das SK, Threadgill D, Magnuson T, Dey SK. Differential expression of the full-length and truncated forms of the epidermal growth factor receptor in the preimplantation mouse uterus and blastocyst. Endocrinology. 1996;137:1492–1496.CrossRefPubMedGoogle Scholar
  12. 12.
    Reiter JL, Threadgill DW, Eley GD, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics. 2001;71(1):1–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Maihle NJ, Flickinger TW, Raines MA, Sanders ML, Kung HJ. Native avian c-erbB gene expresses a secreted protein product corresponding to the ligand-binding domain of the receptor. Proc Natl Acad Sci U S A. 1991;88(5):1825–1829.CrossRefPubMedGoogle Scholar
  14. 14.
    Reiter JL, Maihle NJ. A 1.8 kb alternative transcript from the human epidermal growth factor receptor gene encodes a truncated form of the receptor. Nucleic Acids Res. 1996;24(20):4050–4056.CrossRefPubMedGoogle Scholar
  15. 15.
    Ilekis J, Stark BC, Benveniste R. Expression of Epidermal Growth Factor Receptors at the mRNA and Cell Membrane Levels in First Trimester and Term Human Placentae. New York: Plenum; 1991.Google Scholar
  16. 16.
    Ilekis JV, Stark BC, Scoccia B. Possible role of variant RNA transcripts in the regulation of epidermal growth factor receptor expression in human placenta. Mol Reprod Dev. 1995;41(2):149–156.CrossRefPubMedGoogle Scholar
  17. 17.
    Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309(5967):418–425.CrossRefPubMedGoogle Scholar
  18. 18.
    Merlino GT, Ishii S, Whang-Peng J, et al. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol. 1985;5(7):1722–1734.PubMedGoogle Scholar
  19. 19.
    Lin CR, Chen WS, Kruiger W, et al. Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science. 1984;224(4651):843–848.CrossRefPubMedGoogle Scholar
  20. 20.
    Weber W, Gill GN, Spiess J. Production of an epidermal growth factor receptor-related protein. Science. 1984;224(4646):294–297.CrossRefPubMedGoogle Scholar
  21. 21.
    Xu YH, Richert N, Ito S, Merlino GT, Pastan I. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A. 1984;81(23):7308–7312.CrossRefPubMedGoogle Scholar
  22. 22.
    Reiter JL, Maihle NJ. Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta. Ann N Y Acad Sci. 2003;995:39–47.CrossRefPubMedGoogle Scholar
  23. 23.
    Baron AT, Lafky JM, Connolly DC, et al. A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera. J Immunol Methods. 1998;219(1–2):23–43.CrossRefPubMedGoogle Scholar
  24. 24.
    Baron AT, Lafky JM, Boardman CH, et al. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1999;8(2):129–137.PubMedGoogle Scholar
  25. 25.
    Baron AT, Lafky JM, Suman VJ, et al. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women. Cancer Epidemiol Biomarkers Prev. 2001;10(11):1175–1185.PubMedGoogle Scholar
  26. 26.
    Baron AT, Cora EM, Lafky JM, et al. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(2):103–113.PubMedGoogle Scholar
  27. 27.
    Baron AT, Boardman CH, Lafky JM, et al. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:306–318.Google Scholar
  28. 28.
    Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994;300:281–290.PubMedGoogle Scholar
  29. 29.
    Cadena DL, Gill GN. Expression and purification of the epidermal growth factor receptor extracellular domain utilizing a polycistronic expression system. Protein Expr Purif. 1993;4(3):177–186.CrossRefPubMedGoogle Scholar
  30. 30.
    Greenfield C, Hiles I, Waterfield MD, et al. Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J. 1989;8(13):4115–4123.PubMedGoogle Scholar
  31. 31.
    Hurwitz DR, Emanuel SL, Nathan MH, et al. EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. J Biol Chem. 1991;266(32):22035–22043.PubMedGoogle Scholar
  32. 32.
    Lax I, Burgess WH, Bellot F, Ullrich A, Schlessinger J, Givol D. Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol. 1988;8(4):1831–1834.PubMedGoogle Scholar
  33. 33.
    Wu D, Wang L, Chi Y, Sato GH, Sato JD. Human epidermal growth factor receptor residue covalently cross-linked to epidermal growth factor receptor. Proc Natl Acad Sci U S A. 1990;87:3151–3155.CrossRefPubMedGoogle Scholar
  34. 34.
    Basu A, Raghunath M, Bishayee S, Das M. Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation. Mol Cell Biol. 1989;9(2):671–677.PubMedGoogle Scholar
  35. 35.
    Ilekis JV, Gariti J, Niederberger C, Scoccia B. Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer. Gynecol Oncol. 1997;65(1):36–41.CrossRefPubMedGoogle Scholar
  36. 36.
    Flickinger TW, Maihle NJ, Kung HJ. An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation. Mol Cell Biol. 1992;12(2):883–893.PubMedGoogle Scholar
  37. 37.
    Granai CO, Gajewski WH, Arena B. Ovarian cancer: issues and management. Cancer J. 1994;7(1):7–11.Google Scholar
  38. 38.
    Harlap S. The epidemiology of ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer of the Ovary. New York: Raven Press, Ltd.; 1993:79–93.Google Scholar
  39. 39.
    Look KY. Evolution of screening for epithelial ovarian carcinoma: the quest for early diagnosis. Semin Surg Oncol. 1994;10(4):261–267.CrossRefPubMedGoogle Scholar
  40. 40.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.CrossRefPubMedGoogle Scholar
  41. 41.
    Ries LAG, Miller BA, Hankey BF. SEER Cancer Statistics Review, 1973–1991. Bethesda, MD: National Cancer Institute; 1997. Report No.: NIH Publ. No. 94-2789.Google Scholar
  42. 42.
    Hartge P, Whittemore AS, Itnyre J, McGowan L, Cramer D. Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group. Obstet Gynecol. 1994;84(5):760–764.PubMedGoogle Scholar
  43. 43.
    Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19(1):3–10.CrossRefPubMedGoogle Scholar
  44. 44.
    Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology. 1998;12(3):399–406; discussion 9–10, 13.PubMedGoogle Scholar
  45. 45.
    Easton DF, Ford D, Bishop DT, Consortium BCL. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet. 1995;56(1):265–271.PubMedGoogle Scholar
  46. 46.
    Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer. 1995;76(2):284–290.CrossRefPubMedGoogle Scholar
  47. 47.
    Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives – findings in a large cohort study. Br J Cancer. 1995;71(6):1340–1342.PubMedGoogle Scholar
  48. 48.
    Whittemore AS, Wu ML, Paffenbarger RS Jr, et al. Personal and environmental characteristics related to epithelial ovarian cancer. II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol. 1988;128(6):1228–1240.PubMedGoogle Scholar
  49. 49.
    Doraiswamy V, Parrott JA, Skinner MK. Expression and action of transforming growth factor alpha in normal ovarian surface epithelium and ovarian cancer. Biol Reprod. 2000;63(3):789–796.CrossRefPubMedGoogle Scholar
  50. 50.
    Berchuck A, Rodriguez GC, Kamel A, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol. 1991;164(2):669–674.PubMedGoogle Scholar
  51. 51.
    Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 1991;47(1):87–98.PubMedGoogle Scholar
  52. 52.
    Scambia G, Benedetti Panici P, Battaglia F, et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol. 1992;10(4):529–535.PubMedGoogle Scholar
  53. 53.
    Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19(3):183–232.CrossRefPubMedGoogle Scholar
  54. 54.
    King CR, Kraus MH, DiFiore PP, Paik S, Kasprzyk PG. Implications of erbB-2 overexpression for basic science and clinical medicine. Semin Cancer Biol. 1990;1(5):329–337.PubMedGoogle Scholar
  55. 55.
    Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res. 1987;47:707–712.PubMedGoogle Scholar
  56. 56.
    Ridderheim M, Andersson A, Cajander S, Tribukait B, Stendahl U, Backstrom T. Release of epidermal growth factor/transforming growth factor alpha by ovarian tumours in vitro. Int J Oncol. 1994;5:781–786.Google Scholar
  57. 57.
    Karlan BY, Platt LD. Ovarian cancer screening. The role of ultrasound in early detection. Cancer. 1995;76(10 Suppl):2011–2015.CrossRefPubMedGoogle Scholar
  58. 58.
    Schwartz PE, Chambers JT, Taylor KJ. Early detection and screening for ovarian cancer. J Cell Biochem. 1995;(Suppl 23):233–237.Google Scholar
  59. 59.
    Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89(10):2068–2075.CrossRefPubMedGoogle Scholar
  60. 60.
    Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995;76(10 Suppl):2092–2096.CrossRefPubMedGoogle Scholar
  61. 61.
    Ruddon RW. Causes of cancer. In: Ruddon RW, ed. Cancer Biology. 3rd ed. New York: Oxford University Press; 1995:231–276.Google Scholar
  62. 62.
    Ozols RF, Rubin SC, Thomas G, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1997:919–986.Google Scholar
  63. 63.
    Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol. 2001;127(2):73–79.CrossRefPubMedGoogle Scholar
  64. 64.
    Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 1990;322(15):1021–1027.CrossRefPubMedGoogle Scholar
  65. 65.
    Wadler S. New developments in the treatment of ovarian cancer. Expert Opin Investig Drugs. 2001;10(6):1167–1172.CrossRefPubMedGoogle Scholar
  66. 66.
    Kaye SB. Future directions for the management of ovarian cancer. Eur J Cancer. 2001;37(Suppl 9):S19–S23.CrossRefPubMedGoogle Scholar
  67. 67.
    Oriel KA, Hartenbach EM, Remington PL. Trends in United States ovarian cancer mortality, 1979–1995. Obstet Gynecol. 1999;93(1):30–33.CrossRefPubMedGoogle Scholar
  68. 68.
    Meden H, Marx D, Rath W, et al. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol. 1994;13(1):45–53.CrossRefPubMedGoogle Scholar
  69. 69.
    Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol. 1997;71(2):173–179.CrossRefPubMedGoogle Scholar
  70. 70.
    Meden H, Marx D, Schauer A, Wuttke W, Kuhn W. Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer. Anticancer Res. 1997;17(1B):757–760.PubMedGoogle Scholar
  71. 71.
    Cheung TH, Wong YF, Chung TKH, Maimonis P, Chang AMZ. Clinical use of serum c-erbB-2 in patients with ovarian masses. Gynecol Obstet Invest. 1999;48(2):133–137.CrossRefPubMedGoogle Scholar
  72. 72.
    Yazici H, Dolapcioglu K, Buyru F, Dalay N. Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients. Cancer Investig. 2000;18(2):110–114.CrossRefGoogle Scholar
  73. 73.
    Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I–II) epithelial ovarian carcinoma. Int J Gynecol Cancer. 2001;11(2):119–129.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Andre T. Baron
    • 1
    Email author
  • Jacqueline M. Lafky
    • 2
  • Cecelia H. Boardman
    • 3
  • Elsa M. Cora
    • 4
  • Marites C. Buenafe
    • 5
  • Dachao Liu
    • 6
  • Alfred Rademaker
    • 6
  • David A. Fishman
    • 7
  • Karl C. Podratz
    • 8
  • Jill L. Reiter
    • 9
  • Nita J. Maihle
    • 9
  1. 1.Division of Hematology, Oncology, Blood and Marrow Transplantation, Department of Internal Medicine, Lucille P. Markey Cancer CenterUniversity of KentuckyLexingtonUSA
  2. 2.Tumor Biology Program, Mayo Clinic–RochesterRochesterUSA
  3. 3.Department of Obstetrics and Gynecology, Medical College of VirginiaVirginia Commonwealth University Health SystemRichmondUSA
  4. 4.Department of Biochemistry and NutritionUniversity of Puerto Rico, Medical Sciences Campus, School of MedicineSan JuanUSA
  5. 5.Department of Family PracticeLexington ClinicLexingtonUSA
  6. 6.Department of Preventive Medicine, Robert H. Lurie Comprehensive Cancer CenterNorthwestern University’s Feinberg School of MedicineChicagoUSA
  7. 7.Department of Obstetrics and GynecologyNew York University School of MedicineNew YorkUSA
  8. 8.Department of Gynecologic Surgery/OncologyMayo Clinic–RochesterRochesterUSA
  9. 9.Department of Obstetrics/Gynecology and Reproductive SciencesYale University School of MedicineNew HavenUSA

Personalised recommendations